| Name | Ceftriaxone sodium hydrate |
| Description | Ceftriaxone sodium hydrate is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. |
| In vivo | Ceftriaxone maintains stability against β-lactamase enzymes produced by many bacteria, yet the β-lactamases from B. fragilis, some Klebsiella species, P. vulgaris, and P. aeruginosa can deactivate it. Ceftriaxone sodium trihydrate exhibits broad-spectrum in vitro activity against both Gram-positive and Gram-negative bacteria, aerobes, and certain anaerobes. It is effective against Staphylococcus aureus strains, whether penicillin-sensitive or penicillin-resistant (MIC90, 2 to 8 mg/L). However, its efficacy is compromised against strains resistant to methicillin or oxacillin. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 145.00 mg/mL (219.17 mM), Sonication is recommended.
|
| Keywords | third-generation | damages | cephalosporin | Bacterial | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Ethyl linoleate | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | Stem Cell Differentiation Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |